Related Experiment Video
Updated: Aug 6, 2026
Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Published on: February 2, 2024
Pancreatic cancer: from bench to 5-year survival
Jörg Kleeff1, Christoph Michalski, Helmut Friess
1Department of General Surgery, University of Heidelberg, Heidelberg, Germany.
Abstract:
Pancreatic ductal adenocarcinoma is one of the most aggressive human malignancies, with an overall 5-year survival rate of less than 4%. On the molecular level, an increasing number of genetic and epigenetic alterations have been discovered, with a particular focus on growth factors and related pathways. Small-molecule tyrosine kinase inhibitors, antibodies, and other approaches have been developed in recent years to target these signal transduction pathways, and first clinical trials show encouraging results. In addition, molecular alterations have been identified that enable the cancer cells to invade the perineurium and the retroperitoneal space, thus explaining at least in part the high rate of local recurrence and the severe pain syndrome. Technically, pancreatic surgery has advanced, with acceptable morbidity and mortality rates in high-volume centers. Randomized controlled trials are increasingly carried out to define the best palliative and adjuvant therapy for this disease. Translational research combined with clinical trials will hopefully lead to improved survival and better quality of life for pancreatic cancer patients in the future.
Insights
Pancreatic cancer remains aggressive with poor survival. Research focuses on molecular targets and advanced treatments, offering hope for improved patient outcomes and quality of life.
Area of Science:
- Oncology
- Molecular Biology
- Surgical Oncology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a dismal 5-year survival rate below 4%.
- Numerous genetic and epigenetic alterations, particularly in growth factor pathways, drive PDAC progression.
- Cancer cell invasion mechanisms contribute to high local recurrence rates and severe pain syndromes.
Purpose of the Study:
- To review recent advancements in understanding and treating pancreatic cancer.
- To highlight the development of targeted therapies and surgical improvements.
- To emphasize the role of translational research in improving patient survival and quality of life.
Main Methods:
- Review of current literature on pancreatic cancer molecular pathways and therapeutic strategies.
- Analysis of clinical trial data for targeted therapies like tyrosine kinase inhibitors and antibodies.
- Evaluation of advancements in pancreatic surgery and palliative care approaches.
Main Results:
- Targeted therapies show encouraging early clinical trial results.
- Molecular insights explain cancer cell invasion and associated symptoms.
- Surgical techniques have improved, with acceptable outcomes in specialized centers.
Conclusions:
- Targeting molecular pathways and advancing surgical techniques are crucial for improving pancreatic cancer treatment.
- Ongoing translational research and clinical trials are essential for enhancing survival and quality of life for patients.
- Multidisciplinary approaches combining molecular therapies, surgery, and palliative care offer the most promising future for pancreatic cancer management.
